Expanded CDMO And EU Investments Will Unlock Future Injectables Markets

AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Published
26 Dec 24
Updated
31 Jul 25
AnalystConsensusTarget's Fair Value
€78.95
32.7% undervalued intrinsic discount
31 Jul
€53.15
Loading
1Y
-32.8%
7D
-4.3%

Author's Valuation

€79.0

32.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 2.35%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 1.10%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 3.21%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 2.92%

AnalystConsensusTarget has decreased revenue growth from 9.6% to 8.5% and increased future PE multiple from 19.2x to 21.9x.

Shared on19 Mar 25
Fair value Decreased 0.33%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Decreased 2.83%

AnalystConsensusTarget has increased revenue growth from 8.4% to 10.0% and decreased future PE multiple from 22.1x to 18.8x.